{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:01:03Z","timestamp":1773504063706,"version":"3.50.1"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.2169\/internalmedicine.3091-19","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T22:03:32Z","timestamp":1562709812000},"page":"3069-3075","source":"Crossref","is-referenced-by-count":8,"title":["Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan"],"prefix":"10.2169","volume":"58","author":[{"given":"Motoh","family":"Iwasa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Kato","sequence":"additional","affiliation":[{"name":"Medical Corporation, Kenseikai, Kato Michio Clinic of Liver Diseases, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Isoai","sequence":"additional","affiliation":[{"name":"Blood Purification Business Division, Asahi Kasei Medical Co., Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Blood Purification Business Division, Asahi Kasei Medical Co., Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Torii","sequence":"additional","affiliation":[{"name":"Blood Purification Business Division, Asahi Kasei Medical Co., Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Soneda","sequence":"additional","affiliation":[{"name":"Blood Purification Business Division, Asahi Kasei Medical Co., Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","volume":"38","author":"KP Moore","year":"2003","unstructured":"1. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38: 258-266, 2003.","journal-title":"Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 51: 629-650, 2016.","DOI":"10.1007\/s00535-016-1216-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 40: 484-488, 2004.","DOI":"10.1002\/hep.20317"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5. G\u00fclberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 66: 127-130, 2002.","DOI":"10.1159\/000065593"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6. Gin\u00e8s P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 325: 829-835, 1991.","DOI":"10.1056\/NEJM199109193251201"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7. Sol\u00e0 E, Sanchez-Cab\u00fas S, Rodriguez E, et al. Effects of alfapump\u2122 system on kidney and circulatory function in patients with cirrhosis and refractory ascites. Liver Transpl 23: 583-593, 2017.","DOI":"10.1002\/lt.24763"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8. Kozaki K, IInuma M, Takagi T, et al. Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial 20: 376-382, 2016.","DOI":"10.1111\/1744-9987.12469"},{"key":"8","unstructured":"9. Hanafusa N, Isoai A, Ishihara T, et al. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. PLoS One 12: e0177303, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"10. Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol 45: 979-987, 2010.","DOI":"10.1007\/s00535-010-0240-6"},{"key":"10","unstructured":"11. Sakaida I, Kawazoe S, Kajimura K, et al.; ASCITES-DOUBLEBLIND Study Group. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 44: 73-82, 2014."},{"key":"11","unstructured":"12. The Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 6th ed. Kanehara, Tokyo, 2015: 26."},{"key":"12","doi-asserted-by":"crossref","unstructured":"13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Ito T, Hanafusa N, Fukui M, et al. Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites. Ther Apher Dial 18: 87-92, 2014.","DOI":"10.1111\/1744-9987.12049"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 117: 215-220, 1992.","DOI":"10.7326\/0003-4819-117-3-215"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16. Light RW. Clinical practice. Pleural effusion. N Engl J Med 346: 1971-1977, 2002.","DOI":"10.1056\/NEJMcp010731"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Ito T, Hanafusa N, Iwase S, et al. Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. Int J Clin Oncol 20: 623-628, 2015.","DOI":"10.1007\/s10147-014-0750-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Zaak D, Paquet KJ, Kuhn R. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Z Gastroenterol 39: 5-10, 2001.","DOI":"10.1055\/s-2001-10707"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53: 397-417, 2010.","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.20364","volume":"40","author":"F Salerno","year":"2004","unstructured":"20. Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40: 629-635, 2004.","journal-title":"Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"20","unstructured":"21. Garc\u00eda-Compean D, Blanc P, Larrey D, et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large-volume paracentesis: a randomized controlled trial. Ann Hepatol 1: 29-35, 2002."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_3091-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T03:43:53Z","timestamp":1572666233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_3091-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":20,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3091-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}